Absolute change in fasting plasma glucose over 12 months is associated with 2-year and 5-year major adverse cardiovascular events in patients with drug-eluting stent implants

International Journal of Cardiology

Volumn 179, Issue , 2015, Pages 146-152

  Kang, Dong Oh ^a   Seo, Hong Seog ^a   Choi, Byung Geol ^a   Lee, Eunmi ^b   Kim, Ji Park ^a   Lee, Sun Ki ^a   Im, Sung Il ^a   Na, Jin Oh ^a   Choi, Cheol Ung ^a   Lim, Hong Euy ^a   Kim, Jin Won ^a   Kim, Eung Ju ^a   Rha, Seung Woon ^a   Park, Chang Gyu ^a   Oh, Dong Joo ^a  

^a Korea University College of Medicine   (South Korea)

^b Wonkwang University   (South Korea)

Author keywords

Blood glucose; Diabetes mellitus; Major adverse cardiac event; Statins

Indexed keywords

GLUCOSE; STATIN (PROTEIN); GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG ELUTING STENT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; SURVIVAL; ADVERSE EFFECTS; AGED; BLOOD; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; FOLLOW UP; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; RISK FACTOR; TIME; TREATMENT OUTCOME; TRENDS;

AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; COHORT STUDIES; DRUG-ELUTING STENTS; FASTING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84920657603     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.10.164     Document Type: Article

References (36)

1. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
2. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J. Am. Coll. Cardiol. 44 2004 720 732
3. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N. Engl. J. Med. 339 1998 229 234
4. J. Stamler, O. Vaccaro, J.D. Neaton, and D. Wentworth Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 1993 434 444
5. P.M. Ridker, N. Rifai, L. Rose, J.E. Buring, and N.R. Cook Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N. Engl. J. Med. 347 2002 1557 1565
6. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874
7. P. Libby, P.M. Ridker, G.K. Hansson, and Leducq Transatlantic Network on A Inflammation in atherosclerosis: from pathophysiology to practice J. Am. Coll. Cardiol. 54 2009 2129 2138
8. Emerging Risk Factors C, N. Sarwar, and P. Gao Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies Lancet 375 2010 2215 2222
9. S.G. Wannamethee, A.G. Shaper, P.H. Whincup, L. Lennon, and N. Sattar Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors Arch. Intern. Med. 171 2011 404 410
10. R. Antonicelli, R. Gesuita, M. Boemi, E. Paciaroni, and Study G. Camerano Random fasting hyperglycemia as cardiovascular risk factor in the elderly: a 6-year longitudinal study Clin. Cardiol. 24 2001 341 344
11. J. Kuusisto, L. Mykkanen, K. Pyorala, and M. Laakso NIDDM and its metabolic control predict coronary heart disease in elderly subjects Diabetes 43 1994 960 967
12. M. Wei, S.P. Gaskill, S.M. Haffner, and M.P. Stern Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study Diabetes Care 21 1998 1167 1172
13. J. Armitage The safety of statins in clinical practice Lancet 370 2007 1781 1790
14. C. Baigent, A. Keech, and P.M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
15. Cholesterol Treatment Trialists C, P.M. Kearney, and L. Blackwell Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
16. J. Davignon Beneficial cardiovascular pleiotropic effects of statins Circulation 109 2004 III39 III43
17. C.G. Mihos, M.J. Salas, and O. Santana The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review Cardiol. Rev. 18 2010 298 304
18. S.N. Rajpathak, D.J. Kumbhani, J. Crandall, N. Barzilai, M. Alderman, and P.M. Ridker Statin therapy and risk of developing type 2 diabetes: a meta-analysis Diabetes Care 32 2009 1924 1929
19. N. Sattar, D. Preiss, and H.M. Murray Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
20. D. Preiss, S.R. Seshasai, and P. Welsh Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
21. R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, and H.A. Neil 10-year follow-up of intensive glucose control in type 2 diabetes N. Engl. J. Med. 359 2008 1577 1589
22. S.A. Segel, D.S. Paramore, and P.E. Cryer Hypoglycemia-associated autonomic failure in advanced type 2 diabetes Diabetes 51 2002 724 733
23. H.C. Gerstein, M.E. Miller, and R.P. Byington Effects of intensive glucose lowering in type 2 diabetes N. Engl. J. Med. 358 2008 2545 2559
24. A. Patel, S. MacMahon, and J. Chalmers Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N. Engl. J. Med. 358 2008 2560 2572
25. S. Zoungas, A. Patel, and J. Chalmers Severe hypoglycemia and risks of vascular events and death N. Engl. J. Med. 363 2010 1410 1418
26. N. Rautio, J. Jokelainen, and H. Oksa Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project BMJ Open 2012 2
27. R. Sukhija, S. Prayaga, and M. Marashdeh Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients J. Invest. Med. 57 2009 495 499
28. K.K. Koh, M.J. Quon, S.H. Han, Y. Lee, S.J. Kim, and E.K. Shin Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients J. Am. Coll. Cardiol. 55 2010 1209 1216
29. S. Simsek, C.G. Schalkwijk, and B.H. Wolffenbuttel Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes - the CORALL Study Diabet. Med. 29 2012 628 631
30. J.T. Gwynne, and J.F. Strauss III The role of lipoproteins in steroidogenesis and cholesterol metabolism in steroidogenic glands Endocr. Rev. 3 1982 299 329
31. M. Kanat, E. Serin, and A. Tunckale A multi-center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with Type 2 diabetes (MODEST Study) J. Endocrinol. Invest. 32 2009 852 856
32. M. Bohm, W. Herrmann, S. Wassmann, U. Laufs, and G. Nickenig Does statin therapy influence steroid hormone synthesis? Z. Kardiol. 93 2004 43 48
33. A.S. Dobs, P.S. Sarma, and D. Schteingart Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Metab. Clin. Exp. 42 1993 1146 1152
34. A.S. Dobs, H. Schrott, and M.H. Davidson Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia Metab. Clin. Exp. 49 2000 1234 1238
35. D. Travia, F. Tosi, C. Negri, G. Faccini, P. Moghetti, and M. Muggeo Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads J. Clin. Endocrinol. Metab. 80 1995 836 840
36. E. Selvin, C.M. Crainiceanu, F.L. Brancati, and J. Coresh Short-term variability in measures of glycemia and implications for the classification of diabetes Arch. Intern. Med. 167 2007 1545 1551